C4 Therapeutics (CCCC) EBITDA (2019 - 2026)

C4 Therapeutics' EBITDA history runs 8 years deep, the most recent figure standing at -$27.8 million for Q1 2026.

• On a quarterly basis, EBITDA rose 4.73% year-over-year to -$27.8 million in Q1 2026; TTM through Mar 2026 was -$113.8 million, a 2.33% increase from a year earlier, with the FY2025 full-year figure at -$115.2 million, up 3.67% from the prior year.
• EBITDA fell to -$27.8 million in Q1 2026 per CCCC's latest filing, from -$23.1 million in the prior quarter.
• Across five years, EBITDA topped out at -$21.4 million in Q2 2024 and bottomed at -$38.3 million in Q4 2022.
• The 5-year median for EBITDA is -$31.4 million (2022), against an average of -$31.2 million.
• Across the five-year window, EBITDA plunged 151.02% in 2022 and jumped 42.92% in 2024, its largest moves.
• Year by year, EBITDA stood at -$38.3 million in 2022, then advanced by 2.26% to -$37.4 million in 2023, then decreased by 0.75% to -$37.7 million in 2024, then soared by 38.62% to -$23.1 million in 2025, then fell by 20.05% to -$27.8 million in 2026.
• Per Business Quant, the three latest CCCC EBITDA figures stand at -$27.8 million (Q1 2026), -$23.1 million (Q4 2025), and -$34.4 million (Q3 2025).